FIG 2.

Investigator-assessed tumor response and ANC over the course of treatment. A timeline is included for each patient showing treatment interruptions (gray bars) and dose reductions of oral rucaparib (twice a day or once daily) and SG (administered intravenously on days 1 and 8 of a 21-day cycle), as well as administration of growth factors. Dotted line indicates the threshold for partial response (30% decrease from baseline). ANC, absolute neutrophil count; R, rucaparib; SG, sacituzumab govitecan. ^aEvaluated per RECIST v1.1.